Skip to main content
Clinical Trials/NCT06707584
NCT06707584Not yet recruitingNot Applicable

Role of MRI in Detection of Breast Cancer Molecular Subtypes in Correlation With Immunohistochemistry Results

Lamiaa Gomaa Ahmed Elsayed0 sites45 target enrollmentStarted: April 1, 2025Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Enrollment
45
Primary Endpoint
accuracy of MRI in breast cancer subtyping

Study Overview

Brief Summary

efficacy of MRI in detection of breast cancer molecular subtypes instead of biopsy and immunohistochemistry

Detailed Description

2.4.4 -Study tools (in detail, e.g., lab methods, instruments, steps, chemicals, ...): Patient with breast cancer (malignant breast mass) will do MRI breast and molecular subtypes will be assessed

MRI imaging studies will performed on a 1.5 T scanner , The patient is placed in the prone position with both breasts placed adequately in a double breast coil (four-channel phased array coil), MRI sequences are:

  1. Axial T1WI. 2. Axial T2WI. 3. Axial STIR. 4. DCE-MRI with post-processing subtraction images 5- Axial DWI at b value( 0, 400, 800 and 1000 mm^2 per second) and ADC map will performed 6. MRI spectroscopy MRI acquisition protocol MRI protocols includes
  • Axial T2-weighted fast spin echo sequence: TR=3840 ms, TE=81 ms, slice thickness=3.5 mm, and matrix=448×448.
  • Coronal T2-weighted fast spin echo sequence: TR=3840 ms, TE=81 ms, slice thickness=3.5 mm, and matrix=448×448.s
  • Short tau inversion recovery - axial: TR=8540 ms, TE=59 ms, TI=170 ms, slice thickness=3.5 mm, and matrix=320×314.4.
  • The standard dynamic protocol commenced with a coronal three-dimensional rapid Field echo (thrive) sense non-enhanced T1-weighted sequence.
  • A gadolinium containing contrast was administered at a dose of 0.2 ml/ kg by power injection at a speed of 2.0 ml/s and flushed with 20 ml of saline solution at the same rate.
  • Dynamic imaging was then done in five consecutive series at 90-s intervals. Standard subtraction images were obtained by subtracting precontract images from the early peak postcontrast image.

Study Design

Study Type
Observational
Observational Model
Other
Time Perspective
Other

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • a. patients with breast cancer confirmed by histopathology,

Exclusion Criteria

  • breast implants
  • general Contraindication of MRI as claustrophobia

Outcomes

Primary Outcomes

accuracy of MRI in breast cancer subtyping

Time Frame: 5 years

To investigate the diagnostic accuracy of dynamic post contrast imaging MRI in evaluation of breast cancer molecular subtypes and DWI and ADC in detection of breast cancer molecular subtypes

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Lamiaa Gomaa Ahmed Elsayed
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Lamiaa Gomaa Ahmed Elsayed

Dr

Assiut University

Similar Trials